Regeneron has leveraged its monoclonal ... With the recent EU approval in chronic obstructive pulmonary disease, we now model $21 billion in peak Dupixent sales by 2029. While the partnership ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

People over the age of 50 who have severe mental illness are more likely than the general population to experience fragility fractures but may be less likely to get a diagnosis for osteoporosis ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD ... to approve Sanofi and Regeneron's big-selling IL-4 and IL ...

Sanofi and Regeneron have claimed the first ... The drug is also being tested in some forms of chronic obstructive pulmonary disease (COPD) and various conditions leading to urticaria (hives ...

Regeneron's drug Dupixent received approval for treating Chronic Obstructive Pulmonary Disease in the U.S. and China, a development that TD Cowen believes could represent a $2-3 billion opportunity.